Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

18/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
15/09	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 55.99B 52.96B 48.03B 90.24B 6,110B 90.73B 633B 244B 3,118B 239B 234B 10,022B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 71.2B 67.35B 61.09B 115B 7,770B 115B 805B 311B 3,966B 304B 297B 12,746B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

18/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
15/09	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
02/09	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
08/04	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
01/04	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
30/03	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
19/03	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
05/03	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
13/11	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
01/07/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
13/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.11%	+2.76%	+63.52%	+115.51%	1,055B
JOHNSON & JOHNSON	+0.27%	+0.73%	+51.33%	+73.10%	654B
ABBVIE INC.	+0.73%	+0.88%	+20.70%	+73.89%	467B
ROCHE HOLDING AG	-1.36%	-0.39%	+40.20%	+41.03%	348B
NOVARTIS AG	+1.34%	+5.47%	+23.37%	+31.30%	275B
ASTRAZENECA PLC	-0.48%	-0.06%	+13.56%	+12.36%	258B
AMGEN INC.	+0.85%	+8.42%	+53.17%	+55.45%	224B
GILEAD SCIENCES, INC.	+0.85%	+1.40%	+35.78%	+101.47%	187B
NOVO NORDISK A/S	-0.30%	-10.41%	-27.62%	-61.04%	171B
Average	+0.03%	+0.74%	+30.45%	+49.23%	404.26B
Weighted average by Cap.	-0.11%	+1.32%	+40.69%	+69.05%

	2018	2019
Net sales	15.79B 13.88B 13.13B 11.91B 22.38B 1,515B 22.5B 157B 60.6B 773B 59.27B 57.99B 2,485B	16.09B 14.15B 13.38B 12.14B 22.81B 1,544B 22.93B 160B 61.76B 788B 60.4B 59.09B 2,533B
Net income	-5.1B -4.48B -4.24B -3.85B -7.22B -489B -7.26B -50.65B -19.56B -250B -19.13B -18.72B -802B	-5.27B -4.64B -4.38B -3.98B -7.47B -506B -7.51B -52.38B -20.23B -258B -19.79B -19.36B -830B
Net Debt	21.89B 19.25B 18.21B 16.52B 31.03B 2,101B 31.2B 218B 84.03B 1,072B 82.18B 80.4B 3,446B	17.3B 15.22B 14.4B 13.06B 24.53B 1,661B 24.66B 172B 66.43B 848B 64.96B 63.56B 2,724B

End-of-day quote NYSE
- ^USD	-